https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/using-new-wearable-technology-monitor-niemann-pick-disease/
Using new wearable technology to monitor Niemann-Pick disease
22 Mar 2016, 4:15 p.m.
A smartphone app, combined with wearable technology, will allow doctors to remotely monitor patients with conditions that limit their ability to voluntarily move their muscles. The app, known as 'aparito', uses a motion-tracking writsband to record the movements of patients with ataxia, and other related ambulatory conditions.
The data from the tracker is sent via a smartphone app, where it can be combined with other information such as medication adherence and events such as falls or seizures. Healthcare professionals can have constant access to this information via the web.
Great Ormond Street BRC-researcher Professor Paul Gissen, has been working closely with aparito, and Great Ormond Street Hospital is to be the first in the UK to use this new wearable technology in clinical practice. Patients could receive fewer tests and have shorter hospital visits by using the app, which will monitor routine activity in a continuous, non-invasive way.
NIHR launches £13.7m investment into brain tumour research
The National Institute for Health and Care Research (NIHR) has announced a £13.7 million investment that will support ground-breaking research to develop novel brain tumour treatments in the UK.
New consortium aims to help improve care for arthritis patients
A new UK-led research group, including Great Ormond Street Hospital and University College London, aims to improve the lives of children, young people and adults with arthritis by defining for the first time what being in ‘remission’ from arthritis truly
Update for patients and families on industrial action - December 2025
As you may be aware, some of our Resident Doctors will be taking part in planned industrial action from 7am on Wednesday 17 December to 7am on Monday 22 December.
‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-Cell leukaemia
A groundbreaking new treatment using gene-edited immune cells, developed at GOSH and UCL has shown promising results in helping children and adults fight a rare and aggressive cancer